Elucid AI-PREDICT study begins testing lesion-level heart attack risk with CCTA
Elucid’s AI-PREDICT study will test whether CCTA plaque analysis can identify the coronary lesions most likely to cause a heart attack.
Medical Devices & Diagnostics
Medical Devices & Diagnostics
Can Cleerly’s AI platform replace invasive IVUS? INVICTUS registry data suggest noninvasive parity
Cleerly's INVICTUS registry shows AI-QCT matches IVUS in coronary plaque quantification. Read the clinical analysis.